These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 25698450)

  • 21. Randomized multicenter phase II study of gemcitabine versus docetaxel as first-line therapy with second-line crossover in advanced-stage non-small-cell lung cancer.
    Manegold C; Pilz LR; Koschel G; Romer KS; Mezger J; Hruska D; Dornof W; Gosse H; Gatzemeier U
    Clin Lung Cancer; 2005 Nov; 7(3):208-14. PubMed ID: 16354317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.
    Rebattu P; Quantin X; Ardiet C; Morere JF; Azarian MR; Schuller-Lebeau MP; Pujol JL
    Lung Cancer; 2001; 33(2-3):277-87. PubMed ID: 11551423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy.
    Chen YM; Perng RP; Shih JF; Tsai CM; Whang-Peng J
    J Thorac Oncol; 2006 Jul; 1(6):545-50. PubMed ID: 17409915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly.
    Leong SS; Toh CK; Lim WT; Lin X; Tan SB; Poon D; Tay MH; Foo KF; Ho J; Tan EH
    J Thorac Oncol; 2007 Mar; 2(3):230-6. PubMed ID: 17410046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG).
    Kotsakis A; Kentepozidis N; Emmanouilidis Ch; Polyzos A; Agelidou A; Vaslamatzis M; Chandrinos V; Agelaki S; Vamvakas L; Kalbakis K; Katsaounis P; Stoltidis D; Nintos G; Hatzidaki D; Vetsika EK; Mavroudis D; Georgoulias V
    Lung Cancer; 2015 Apr; 88(1):57-62. PubMed ID: 25662596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
    Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
    Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial.
    Quoix E; Audigier-Valette C; Lavolé A; Molinier O; Westeel V; Barlesi F; Le Treut J; Pichon E; Dauba J; Otto J; Moreau L; Madelaine J; Dumont P; Margery J; Debieuvre D; Renault PA; Pujol JL; Langlais A; Morin F; Moro-Sibilot D; Souquet PJ
    Eur J Cancer; 2020 Oct; 138():193-201. PubMed ID: 32898792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Spigel DR; Farley C; Shipley DL; Bearden JD; Gandhi J; Ann Houston G; Anthony Greco F
    Cancer; 2007 Nov; 110(9):2027-34. PubMed ID: 17823908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.
    Maruyama R; Nishiwaki Y; Tamura T; Yamamoto N; Tsuboi M; Nakagawa K; Shinkai T; Negoro S; Imamura F; Eguchi K; Takeda K; Inoue A; Tomii K; Harada M; Masuda N; Jiang H; Itoh Y; Ichinose Y; Saijo N; Fukuoka M
    J Clin Oncol; 2008 Sep; 26(26):4244-52. PubMed ID: 18779611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.
    Wu YL; Sequist LV; Tan EH; Geater SL; Orlov S; Zhang L; Lee KH; Tsai CM; Kato T; Barrios CH; Schuler M; Hirsh V; Yamamoto N; O'Byrne K; Boyer M; Mok T; Peil B; Märten A; Chih-Hsin Yang J; Paz-Ares L; Park K
    Clin Lung Cancer; 2018 Jul; 19(4):e465-e479. PubMed ID: 29653820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer.
    Novello S; Falcone A; Crinò L; Rinaldi M; Nardi M; De Marinis F; Tonato M; Tibaldi C; Tinazzi A; Russo F; Grassivaro N; Scagliotti GV
    Lung Cancer; 2009 Dec; 66(3):327-32. PubMed ID: 19329221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial.
    Tas F; Demir C; Camlica H; Ustuner Z; Topuz E
    Med Oncol; 2004; 21(3):233-40. PubMed ID: 15456950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
    Kim ES; Hirsh V; Mok T; Socinski MA; Gervais R; Wu YL; Li LY; Watkins CL; Sellers MV; Lowe ES; Sun Y; Liao ML; Osterlind K; Reck M; Armour AA; Shepherd FA; Lippman SM; Douillard JY
    Lancet; 2008 Nov; 372(9652):1809-18. PubMed ID: 19027483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.
    D'Addario G; Rauch D; Stupp R; Pless M; Stahel R; Mach N; Jost L; Widmer L; Tapia C; Bihl M; Mayer M; Ribi K; Lerch S; Bubendorf L; Betticher DC
    Ann Oncol; 2008 Apr; 19(4):739-45. PubMed ID: 18096565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
    Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
    J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
    Giaccone G; Herbst RS; Manegold C; Scagliotti G; Rosell R; Miller V; Natale RB; Schiller JH; Von Pawel J; Pluzanska A; Gatzemeier U; Grous J; Ochs JS; Averbuch SD; Wolf MK; Rennie P; Fandi A; Johnson DH
    J Clin Oncol; 2004 Mar; 22(5):777-84. PubMed ID: 14990632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pooled analysis of elderly patients with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: the Hellenic Oncology Research Group experience.
    Pallis AG; Polyzos A; Boukovinas I; Agelidou A; Lamvakas L; Tsiafaki X; Agelidou M; Pavlakou G; Chandrinos V; Kakolyris S; Christophyllakis C; Kentepozidis N; Giassas S; Androulakis N; Agelaki S; Georgoulias V
    J Thorac Oncol; 2008 May; 3(5):505-10. PubMed ID: 18449003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.
    Fidias PM; Dakhil SR; Lyss AP; Loesch DM; Waterhouse DM; Bromund JL; Chen R; Hristova-Kazmierski M; Treat J; Obasaju CK; Marciniak M; Gill J; Schiller JH
    J Clin Oncol; 2009 Feb; 27(4):591-8. PubMed ID: 19075278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.